Trial Profile
Identification of tissue biomarkers related to late toxicity in Head and Neck Cancer Patients treated with chemoradiotherapy or bioradiotherapy
Status:
Recruiting
Phase of Trial:
Phase IV
Latest Information Update: 08 Mar 2016
Price :
$35
*
At a glance
- Drugs Cetuximab (Primary)
- Indications Head and neck cancer
- Focus Biomarker; Pharmacodynamics
- Acronyms BioLateTox
- 08 Mar 2016 New trial record